Comparison of transcript levels in peripheral blood samples from the IBS participants across all three treatment arms at baseline and 6-weeks indicated that EGR1 gene expression was significantly reduced across all treatment arms (log fold-change −0.15; p = 0.02; N = 188). The gene discussed is EGR1; the disease is irritable bowel syndrome.